This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Mar 20;14(4):200.

doi: 10.1038/nrclinonc.2017.26.

Targeted therapies: Ibrutinib: new option for relapsed MZL

Lisa Hutchinson

PMID: 28316331
DOI: 10.1038/nrclinonc.2017.26

Comment

Targeted therapies: Ibrutinib: new option for relapsed MZL

Lisa Hutchinson. Nat Rev Clin Oncol. 2017.

. 2017 Mar 20;14(4):200.

doi: 10.1038/nrclinonc.2017.26.

Author

Lisa Hutchinson

PMID: 28316331
DOI: 10.1038/nrclinonc.2017.26

No abstract available

PubMed Disclaimer

Comment on

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Noy A, et al. Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6. Blood. 2017. PMID: 28167659 Free PMC article. Clinical Trial.

References

1. Blood. 2017 Feb 6;:null - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations